Home monitoring for wet AMD treatment
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a home monitoring app (OKKO Health) for people with wet age-related macular degeneration (AMD). It aims to see if using the app helps track the disease and guide treatment decisions by your doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 55 years or older.
- You have wet AMD in one eye (the study eye).
- You have not yet started treatment, or you have been on anti-VEGF injections for less than 48 weeks.
- Your vision in the study eye is between 20/20 and 20/200 (mild to moderate loss of sharpness).
- You own a working smartphone or tablet that can run the OKKO Health app.
- You are willing to use the app and attend clinic visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a home monitoring system using a webcam to check for signs of wet AMD returning. It may help you manage your condition between doctor visits and catch problems early.
This study tests a web-based system that uses eye tracking to check vision in people being treated for wet age-related macular degeneration (AMD). It may help monitor your recovery without needing as many clinic visits.
This study tests a new investigational drug called BETA-TT8 for people with wet age-related macular degeneration (wet AMD) who have already been treated with standard therapy (aflibercept). The goal is to see if this new treatment is safe and effective in improving vision.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This trial tests an AI system designed to catch early signs of late age-related macular degeneration (AMD) before it's diagnosed. It's for people who haven't yet been diagnosed with AMD or treated for retinal disease.
Hear when a new Exudative Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.